Validation of uHear™ as a Screening Tool to Detect Hearing Impairment in Elderly Cancer Patients Within a Comprehensive Geriatric Assessment

Overview

Over the last few years, there has been a considerable interest in the development of screening tools to assess the capability of elderly cancer patients to tolerate anti-cancer treatment. Therefore, the NCCN Guidelines in Senior Adult Oncology recommend an assessment of co-morbid conditions that are likely to interfere with cancer treatment and tolerability. As presbyacusis is common in an older population, elderly cancer patients are at high risk for social isolation and a reduced quality of life. Therefore, in this project the investigators aim to validatie uHear™ as a quick and reliable screening tool to screen for presbyacusisf in routine clinical oncology practice.

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: June 2015

Clinical Trial Outcome Measures

Primary Measures

  • Validation of uHear™ as a screening tool to detect hearing loss in elderly cancer patients
    • Time Frame: Baseline

Secondary Measures

  • To determine the prevalence of presbyacusis in an elderly cancer population
    • Time Frame: Baseline
  • To compare objective and subjective hearing screening measures
    • Time Frame: Baseline
  • To measure hearing impairment in G8 positive patients compared with G8 negative patients
    • Time Frame: Baseline
  • To compare uHear™ with the Whispered Voice Test
    • Time Frame: Baseline
  • To evaluate the use of uHear™ as a measure to determine eligibility for cisplatin treatment in elderly cancer patients
    • Time Frame: Baseline

Participating in This Clinical Trial

Inclusion Criteria

  • Patients should have reached the age of 70 or more at enrolment – Histologically confirmed diagnosis of solid cancer or hematologic malignancy. All stages of cancer are eligible – Patients should be fluent in Dutch or French – Patients must receive their primary oncology care in the participating hospital – Patients should be cognitively capable of performing the audiology assessment – Patients should have signed informed consent Exclusion Criteria:

  • Patients who do not match the above inclusion criteria – Patients who are visiting the oncology clinic for a second opinion and do not wish to be treated in this clinic – Patients presenting with clinically diagnosed Ménière's disease, retrocochlear hearing loss, autoimmune inner ear disease, fluctuating hearing loss or a history of sudden sensory neural hearing loss – Patients who already have a hearing aid or a previously diagnosed hearing loss

Gender Eligibility: All

Minimum Age: 70 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • General Hospital Groeninge
  • Provider of Information About this Clinical Study
    • Principal Investigator: Dr. Philip Debruyne, Medical Oncologist – General Hospital Groeninge
  • Overall Official(s)
    • Philip R Debruyne, MD, PhD, Principal Investigator, Cancer Center, General Hospital Groeninge

Citations Reporting on Results

Lycke M, Boterberg T, Martens E, Ketelaars L, Pottel H, Lambrecht A, Van Eygen K, De Coster L, Dhooge I, Wildiers H, Debruyne PR. Implementation of uHear–an iOS-based application to screen for hearing loss–in older patients with cancer undergoing a comprehensive geriatric assessment. J Geriatr Oncol. 2016 Mar;7(2):126-33. doi: 10.1016/j.jgo.2016.01.008. Epub 2016 Feb 26.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.